Leukotriene C4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 4, 2009, Pages 579-586

  Freiberg, Jacob J ^a   Dahl, Morten ^a   Tybjærg Hansen, Anne ^b,c   Grande, Peer ^d   Nordestgaard, Børge G ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

5 Lipoxygenase pathway; Asthma; Chronic obstructive pulmonary disease; Cysteinyl leukotrienes; Ischemic cerebrovascular disease; Ischemic heart disease; Ischemic stroke; Leukotriene C4 synthase; Transient ischemic attack

Indexed keywords

LEUKOTRIENE C4 SYNTHASE; GLUTATHIONE TRANSFERASE; LEUKOTRIENE-C4 SYNTHASE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; DENMARK; ENZYMOLOGY; FEMALE; GENETICS; HEART MUSCLE ISCHEMIA; INCIDENCE; MIDDLE AGED; STROKE;

ADULT; ASTHMA; DENMARK; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; STROKE;

EID: 61749085692     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.01.002     Document Type: Article

References (46)

1. Freiberg J.J., Tybjaerg-Hansen A., Sillesen H., Jensen G.B., and Nordestgaard B.G. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 28 5 (2008) 990-996
2. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 100 3 (2003) 1238-1243
3. Allen S., Dashwood M., Morrison K., and Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97 24 (1998) 2406-2413
4. Allayee H., Hartiala J., Lee W., Mehrabian M., Irvin C.G., Conti D.V., et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 132 3 (2007) 868-874
5. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 4819 (1987) 1171-1176
6. Hsieh F.H., Lam B.K., Penrose J.F., Austen K.F., and Boyce J.A. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J. Exp. Med. 193 1 (2001) 123-133
7. Sayers I., Sampson A.P., Ye S., and Holgate S.T. Promoter polymorphism influences the effect of dexamethasone on transcriptional activation of the LTC4 synthase gene. Eur. J. Hum. Genet. 11 8 (2003) 619-622
8. Sampson A.P., Siddiqui S., Buchanan D., Howarth P.H., Holgate S.T., Holloway J.W., et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55 Suppl 2 (2000) S28-S31
9. Iovannisci D.M., Lammer E.J., Steiner L., Cheng S., Mahoney L.T., Davis P.H., et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study. Arterioscler. Thromb. Vasc. Biol. 27 2 (2007) 394-399
10. Sanak M., Simon H.U., and Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350 9091 (1997) 1599-1600
11. Schnohr P., Jensen J.S., Scharling H., and Nordestgaard B.G. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur. Heart. J. 23 8 (2002) 620-626
12. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 3 (2007) 299-308
13. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., and Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300 18 (2008) 2142-2152
14. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., Sethi A.A., Remaley A.T., Schnohr P., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 21 (2008) 2524-2532
15. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359 18 (2008) 1897-1908
16. Friberg J., Scharling H., Gadsboll N., and Jensen G.B. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am. J. Cardiol. 92 12 (2003) 1419-1423
17. Truelsen T., Gronbaek M., Schnohr P., and Boysen G. Stroke case fatality in Denmark from 1977 to 1992: the Copenhagen City Heart Study. Neuroepidemiology 21 1 (2002) 22-27
18. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J. Clin. Epidemiol. 41 2 (1988) 105-114
19. Lindgren A., Norrving B., Rudling O., and Johansson B.B. Comparison of clinical and neuroradiological findings in first-ever stroke. A population-based study. Stroke 25 7 (1994) 1371-1377
20. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur. Heart. J. 18 3 (1997) 394-413
21. Sayers I., Barton S., Rorke S., Beghe B., Hayward B., Van Eerdewegh P., et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax 58 5 (2003) 417-424
22. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N. Engl. J. Med. 357 18 (2007) 1841-1854
23. Datta Y.H., Romano M., Jacobson B.C., Golan D.E., Serhan C.N., and Ewenstein B.M. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92 11 (1995) 3304-3311
24. Uzonyi B., Lotzer K., Jahn S., Kramer C., Hildner M., Bretschneider E., et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 103 16 (2006) 6326-6331
25. Porreca E., Di Febbo C., Di Sciullo A., Angelucci D., Nasuti M., Vitullo P., et al. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb. Haemost. 76 1 (1996) 99-104
26. Fisher M., and Folland E. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences. Am. J. Ther. 15 2 (2008) 137-149
27. Hong X., Zhou H., Tsai H.J., Wang X., Liu X., Wang B., et al. Cysteinyl leukotriene receptor 1 gene variation and risk of asthma. Eur. Respir. J. 33 1 (2009) 42-48
28. Kim S.H., Jeong H.H., Cho B.Y., Kim M., Lee H.Y., Lee J., et al. Association of four-locus gene interaction with aspirin-intolerant asthma in Korean asthmatics. J. Clin. Immunol. 28 4 (2008) 336-342
29. Kim S.H., Oh J.M., Kim Y.S., Palmer L.J., Suh C.H., Nahm D.H., et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin. Exp. Allergy 36 4 (2006) 433-439
30. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350 1 (2004) 29-37
31. Strasser T., Fischer S., and Weber P.C. Leukotriene B5 is formed in human neutrophils after dietary supplementation with icosapentaenoic acid. Proc. Natl. Acad. Sci. U. S. A. 82 5 (1985) 1540-1543
32. Koller M., Senkal M., Kemen M., Konig W., Zumtobel V., and Muhr G. Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery. Clin. Nutr. 22 1 (2003) 59-64
33. Lands B. A critique of paradoxes in current advice on dietary lipids. Prog. Lipid. Res. 47 2 (2008) 77-106
34. Lee T.H., Hoover R.L., Williams J.D., Sperling R.I., Ravalese III J., Spur B.W., et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med. 312 19 (1985) 1217-1224
35. Lands W.E. Biochemistry and physiology of n-3 fatty acids. FASEB J. 6 8 (1992) 2530-2536
36. Dahlen S.E., Bjork J., Hedqvist P., Arfors K.E., Hammarstrom S., Lindgren J.A., et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 78 6 (1981) 3887-3891
37. Nagata M., Saito K., Tsuchiya K., and Sakamoto Y. Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J. Allergy Clin. Immunol. 109 4 (2002) 676-680
38. Bousquet J., Jeffery P.K., Busse W.W., Johnson M., and Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 161 5 (2000) 1720-1745
39. Montuschi P., Kharitonov S.A., Ciabattoni G., and Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 58 7 (2003) 585-588
40. Gaki E., Papatheodorou G., Ischaki E., Grammenou V., Papa I., and Loukides S. Leukotriene E(4) in urine in patients with asthma and COPD-the effect of smoking habit. Respir. Med. 101 4 (2007) 826-832
41. Lacoste J.Y., Bousquet J., Chanez P., Van V.T., Simony-Lafontaine J., Lequeu N., et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 92 4 (1993) 537-548
42. Marcus A.J., Broekman M.J., Safier L.B., Ullman H.L., Islam N., Sherhan C.N., et al. Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochem. Biophys. Res. Commun. 109 1 (1982) 130-137
43. Sanz C., Isidro-Garcia M., Davila I., Moreno E., Laffond E., and Lorente F. Analysis of 927T > C CYSLTRI and -444A > C LTC4S polymorphisms in patients with asthma. J. Investig. Allergol. Clin. Immunol. 16 6 (2006) 331-337
44. Van S.R., Stevenson D.D., Baldasaro M., Lam B.K., Zhao J., Yoshida S., et al. 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106 1 Pt 1 (2000) 72-76
45. Cazzola M., Centanni S., Boveri B., Di Marco F., Santus P., Matera M.G., et al. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration 68 5 (2001) 452-459
46. Rubinstein I., Kumar B., and Schriever C. Long-term montelukast therapy in moderate to severe COPD-a preliminary observation. Respir. Med. 98 2 (2004) 134-138